Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia

被引:18
作者
Achalia, Rashmin M. [1 ,3 ]
Chaturvedi, Santosh K. [1 ]
Desai, Geetha [1 ]
Rao, Girish N. [1 ]
Prakash, Om [2 ]
机构
[1] Natl Inst Mental Hlth & Neurosci NIMHANS, Bangalore, Karnataka, India
[2] IHBAS, New Delhi, India
[3] Govt Med Coll, Aurangabad, Maharashtra, India
关键词
Tardive dyskinesia; Prevalence; Risk factors; First generation antipsychotics; Second generation antipsychotics;
D O I
10.1016/j.ajp.2013.12.010
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Tardive dyskinesia (TD) is one of the most distressing side effects of antipsychotic treatment. As prevalence studies of TD in Asian population are scarce, a cross-sectional study was performed to assess the frequency of TD in Indian patients with schizophrenia and risk factors of TD. Method: Cross-sectional study of 160 Indian patients fulfilling the DSM-IV TR criteria for schizophrenia and who received antipsychotics for at least one year, were examined with two validated scales for TD. Logistic regression analyses were used to examine the relationship between TD and clinical risk factors. Results: The frequency of probable TD in the total sample was 26.4%. The logistic regression yielded significant odds ratios between TD and age, intermittent treatment, and total cumulative antipsychotic dose. The difference of TD between SGA and FGA disappeared after adjusting for important co-variables in regression analysis. Conclusion: Indian patients with schizophrenia and long-term antipsychotic treatment have a high risk of TD, and TD is associated with older age, intermittent antipsychotic treatment, and a high total cumulative antipsychotic dose. Our study findings suggest that there is no significant difference between SGAs with regards to the risk of causing TD as compared to FGAs. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 48 条
[1]  
American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th., DOI DOI 10.1176/APPI.BOOKS.9780890425787
[2]  
Atkins M, 1997, PSYCHIAT B, V21, P224, DOI DOI 10.1192/PB.21.4.224
[3]   Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study [J].
Bai, YM ;
Yu, SC ;
Chen, JY ;
Lin, CY ;
Chou, P ;
Lin, CC .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (02) :79-85
[4]   Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol [J].
Beasley, CM ;
Dellva, MA ;
Tamura, RN ;
Morgenstern, H ;
Glazer, WM ;
Ferguson, K ;
Tollefson, GD .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :23-30
[5]  
Bhatia T, 2004, J Postgrad Med, V50, P167
[6]   Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy [J].
Carnahan, RM ;
Lund, BC ;
Perry, PJ ;
Chrischilles, EA .
ACTA PSYCHIATRICA SCANDINAVICA, 2006, 113 (02) :135-141
[7]   A Randomized Controlled Trial of Risperidone and Olanzapine for Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia [J].
Chan, Hung-Yu ;
Chiang, Shu-Chuan ;
Chang, Ching-Jui ;
Gau, Susan S. -F. ;
Chen, Jiahn-Jyh ;
Chen, Chiung-Hsu ;
Hwu, Hai-Gwo ;
Lai, Mei-Shu .
JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (09) :1226-1233
[8]  
Chouinard G., 1982, BIOL PSYCHIAT, V6, P571
[9]   Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies [J].
Correll, CU ;
Leucht, S ;
Kane, JM .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03) :414-425
[10]   A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [J].
Csernansky, JG ;
Mahmoud, R ;
Brenner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :16-22